| __timestamp | Neurocrine Biosciences, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 612613000000 |
| Thursday, January 1, 2015 | 32480000 | 650773000000 |
| Friday, January 1, 2016 | 68081000 | 619061000000 |
| Sunday, January 1, 2017 | 169906000 | 628106000000 |
| Monday, January 1, 2018 | 248932000 | 717599000000 |
| Tuesday, January 1, 2019 | 354100000 | 964737000000 |
| Wednesday, January 1, 2020 | 433300000 | 875663000000 |
| Friday, January 1, 2021 | 583300000 | 886361000000 |
| Saturday, January 1, 2022 | 752700000 | 997309000000 |
| Sunday, January 1, 2023 | 887600000 | 1053819000000 |
| Monday, January 1, 2024 | 1007200000 | 1053819000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Neurocrine Biosciences, Inc. from 2014 to 2023. Over this period, Takeda's SG&A expenses have consistently dwarfed those of Neurocrine, reflecting its expansive global operations. In 2023, Takeda's expenses reached a staggering 1.05 trillion yen, marking a 72% increase from 2014. Meanwhile, Neurocrine's expenses grew by an impressive 4,800%, highlighting its rapid expansion and investment in growth. This stark contrast underscores the diverse strategies employed by these companies: Takeda's focus on maintaining its global footprint and Neurocrine's aggressive growth trajectory. As we look to the future, these trends offer valuable insights into the strategic priorities shaping the pharmaceutical industry.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Takeda Pharmaceutical Company Limited
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: GSK plc vs Neurocrine Biosciences, Inc.
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.